Ankita Thakkar Author

Editorial Open Access

Will PD-1/PD-L1 Inhibitor Become a True Salvage Therapy for Relapsed or Refractory Patients with Hematological Malignancies?

Author(s):

Ankita Thakkar

The treatment of cancer has evolved tremendously with the advent of immunotherapy. The effort of several groups in 1990’s led to the discovery that cancer cells use a specific mechanism called the Programmed death-1 pathway to evade the host immune response. Since then, several drugs and clinical trials have been designed that either block the receptor PD-1 or its ligand PD-L1. Recent approval of four different PD-1/PD-L1 inhibitor drugs avelumab, pembrolizumab, nivolumab and atezolizumab in different solid tumors have established PD-1 inhibition as a promising pathway in other cancers. The primary option for relapsed or refractory patients with hematological malignancies and who is ineligible to hematopoietic stem cell transplantation is chemotherapy.... view more»

DOI: 10.4172/2324-9110.1000e110

Abstract HTML PDF